Original articleAge-Related Macular Degeneration Revisited – Piecing the Puzzle: The LXIX Edward Jackson Memorial Lecture
Section snippets
The Natural History of Age-Related Macular Degeneration
The earliest clinical manifestations of AMD are drusen and pigmentary changes in the macula (Figure 1, Top row). Drusen are focal deposits of extracellular debris that typically form between the retinal pigment epithelium (RPE) and Bruch membrane, and are described clinically by their size and contour.8, 9 Small drusen (<63 μm) are not indicative of AMD and can be seen in the eyes of healthy young and middle-aged adults.10, 11 Intermediate drusen (63 to 125 μm) and large drusen (>125 μm) are
Pathogenesis: An Evolving Story
Our understanding of AMD and its pathogenesis has changed over decades of observation. Although there has been progress, there are still missing pieces in the puzzle, and any attempt at a unified model will meet with disagreement. Nevertheless, formulating a model is a worthwhile exercise and a prerequisite to developing biologically based therapies. However, before developing a model based on current knowledge, it is useful to review the pathogenesis of AMD from a historical perspective.
Senile
Genetics of Age-Related Macular Degeneration
Clinical observations, epidemiologic data, clinicopathologic correlations, and biochemical studies have provided a large body of evidence on which to base models of AMD pathogenesis. The recent revolution in genetic and genomic studies has contributed significantly to our understanding of AMD pathogenesis—in some cases confirming factors identified by other means, and in other cases, identifying new pathways.
Clinical Management of Age-Related Macular Degeneration
The major breakthroughs of the early part of this century have been treatments for neovascular AMD. Therapy for neovascular AMD has progressed from laser photocoagulation to surgery, radiation, and steroids; then to photodynamic therapy (PDT); and finally to anti-VEGF therapy. Current investigations in neovascular AMD are focused on additional antiangiogenic strategies, neuroprotection, and long-term delivery. Ultimately, a better strategy is to attack AMD earlier in the disease to halt
An Integrated Model of Age-Related Macular Degeneration
Clinical observations, imaging, and histopathologic evidence provided the insights for the first attempts to formulate a model of AMD. Epidemiologic observations and biochemical approaches offered further insights into the pathogenic processes. More recently, molecular biology and genetics have increased our understanding, and we may be closer to being able to formulate an integrated model of AMD. The genetic studies suggest that some genes determine the major underlying risk, and others may
Conclusions
Major advances in the treatment of AMD have been based on targeting key components in the pathogenesis of the disease. By interfering with VEGF, the key driver of neovascularization and vascular permeability, we were able to halt neovascular disease in most patients and to improve vision in many. However, neovascularization represents only one of the advanced states of the disease process. Clearly, a greater impact could be achieved by targeting factors earlier in disease pathogenesis, which
Joan W. Miller, MD, FARVO, is the Henry Willard Williams Professor of Ophthalmology and Chair of Ophthalmology at Harvard Medical School. She also serves as and Chief of Ophthalmology at Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital. Her research focuses on ocular neovascular disorders, including age-related macular degeneration (AMD) and diabetic retinopathy. She pioneered the development of the first pharmacologic therapy for AMD, and her research formed the basis of
References (277)
- et al.
The significance of the Edward Jackson lecture
Am J Ophthalmol
(2005) - et al.
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results
Ophthalmology
(2012) - et al.
Reticular pseudodrusen are subretinal drusenoid deposits
Ophthalmology
(2010) - et al.
Combined confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography imaging of reticular drusen associated with age-related macular degeneration
Ophthalmology
(2010) - et al.
Aging and dark adaptation
Vision Res
(1999) - et al.
Cone- and rod-mediated dark adaptation impairment in age-related maculopathy
Ophthalmology
(2007) - et al.
Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes
Surv Ophthalmol
(1999) - et al.
Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration
Am J Pathol
(2005) - et al.
The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis
Ophthalmology
(2010) - et al.
Visual function and dysfunction in early and late age-related maculopathy
Prog Retin Eye Res
(2006)
Hyperopia and neovascularization in age-related macular degeneration
Ophthalmology
Aging changes in Bruch's membrane. A histochemical and morphologic study
Ophthalmology
Hydrodynamics of ageing Bruch's membrane: implications for macular disease
Exp Eye Res
A hemodynamic model of the pathogenesis of age-related macular degeneration
Am J Ophthalmol
Contribution to the theory and practice of tonometry
Am J Ophthalmol
The pathogenesis of age-related macular degeneration
Am J Ophthalmol
Fundus autofluorescence and progression of age-related macular degeneration
Surv Ophthalmol
RPE lipofuscin and its role in retinal pathobiology
Exp Eye Res
Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD)
Prog Retin Eye Res
Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration
Exp Eye Res
Cystatin C in macular and neuronal degenerations: implications for mechanism(s) of age-related macular degeneration
Vision Res
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration
Prog Retin Eye Res
A role for local inflammation in the formation of drusen in the aging eye
Am J Ophthalmol
Antiretinal antibodies in serum of patients with age-related macular degeneration
Ophthalmology
Detection of specific extracellular matrix molecules in drusen, Bruch's membrane, and ciliary body
Am J Ophthalmol
A potential role for immune complex pathogenesis in drusen formation
Exp Eye Res
The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited
Prog Retin Eye Res
Cellular and 3D optical coherence tomography assessment during the initiation and progression of retinal degeneration in the Ccl2/Cx3cr1-deficient mouse
Exp Eye Res
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
N Engl J Med
Age-related macular degeneration
N Engl J Med
Age-related macular degeneration
N Engl J Med
The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report no. 17
Arch Ophthalmol
A simplified severity scale for age-related macular degeneration: AREDS report no. 18
Arch Ophthalmol
The grading and prevalence of macular degeneration in Chesapeake Bay watermen
Arch Ophthalmol
Heredity of small hard drusen in twins aged 20–46 years
Invest Ophthalmol Vis Sci
Risk assessment model for development of advanced age-related macular degeneration
Arch Ophthalmol
A short-duration dark adaptation protocol for assessment of age-related maculopathy
J Ocul Biol Dis Infor
Basal linear deposit and large drusen are specific for early age-related maculopathy
Arch Ophthalmol
Elastic fiber homeostasis requires lysyl oxidase-like 1 protein
Nat Genet
Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye
Am J Pathol
TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration
Invest Ophthalmol Vis Sci
Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration
Br J Ophthalmol
Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD
Invest Ophthalmol Vis Sci
Classification of retinal pigment epithelial detachments associated with drusen
Graefes Arch Clin Exp Ophthalmol
Clinicopathologic correlation of retinal angiomatous proliferation
Arch Ophthalmol
Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation
Retina
Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration
Arch Ophthalmol
Drusen and disciform macular detachment and degeneration
Trans Am Ophthalmol Soc
Cited by (211)
Subretinal drusenoid deposits, age-related macular degeneration, and cardiovascular disease
2024, Asia-Pacific Journal of Ophthalmology2-Hydroxypropyl-β-cyclodextrin mitigates pathological changes in a mouse model of retinal cholesterol dyshomeostasis
2023, Journal of Lipid ResearchComplement activation by RPE cells preexposed to TNFα and IFNγ
2022, Experimental Eye Research
Joan W. Miller, MD, FARVO, is the Henry Willard Williams Professor of Ophthalmology and Chair of Ophthalmology at Harvard Medical School. She also serves as and Chief of Ophthalmology at Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital. Her research focuses on ocular neovascular disorders, including age-related macular degeneration (AMD) and diabetic retinopathy. She pioneered the development of the first pharmacologic therapy for AMD, and her research formed the basis of current antiangiogenic therapies for neovascular AMD.
Supplemental Material available at AJO.com.